Glenmark Pharmaceuticals share news, announcements and annual reports
NSE: GLENMARKBSE: 532296Pharmaceuticals & BiotechnologyMid Cap
Glenmark Pharmaceuticals Limited · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Feb 2000
Last close ₹2,298.70down ₹40.30 (1.72%)BSE ₹2,308.00
Share price at the NSE close on 30 Oct 2026. Previous close ₹2,339.00.
30 Oct: open ₹2,336.00, high ₹2,337.30, low ₹2,291.30
52-week range of traded prices to 30 Oct 2026
₹1,801.40Low, 7 Nov 2025₹2,537.60High, 28 Aug 2026
- Next results date: the board meets on 5 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹64,875 Cr176th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 36.08
- P/E without one-offsPrice to earnings without one-off items. Market cap divided by core profit: the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, less one-off items (exceptional items and the result of businesses sold or closed). Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹1,943 crore of one-off items, the largest of them in the quarter to Sep 2025.
- 17.34
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 6.17
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.11%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 18.6%
- ROE without one-offsReturn on equity without one-off items. Core profit, the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders less one-off items (exceptional items and the result of businesses sold or closed), as a percentage of the same net worth as the return on equity. Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹1,943 crore of one-off items, the largest of them in the quarter to Sep 2025.
- 38.6%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 39.8%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.00
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 4,28,88751.5% delivered
Glenmark Pharmaceuticals share news and announcements
1,381 announcements, routine notices left out, newest first. Page 27 of 28.
Feb 2008
6 Feb · Business
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding a press release dated February 06, 2008, titled "Glenmark's receives USD 15 million as milestone payments from Forest for Oglemilast, GRC 3886". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.6 Feb · Results
Glenmark Pharmaceuticals Ltd. has informed the Exchange that Pursuant to the notice dated December 21, 2007, the shareholders of Glenmark Pharmaceuticals Ltd. have approved through postal ballot the Resolutions at the deemed Extraordinary General Meeting (EGM) held on February 05, 2008. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.1 Feb · Business
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding a press release dated February 01, 2008, titled "Glenmark Pharmaceuticals to get back the Global Rights to Melogliptin, GRC 8200 from Merck Serono". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Jan 2008
28 Jan · Updates
Glenmark Pharmaceuticals Ltd. has informed the Exchange vide its letter dated January 28, 2008, that: "The Compensation Committee of the Company, at its meeting held on 23rd January, 2008 has cancelled 81500 stock options pursuant to ESOS 2003, owing to employees leaving the services of the Company. Further, the Compensation Committee has issued 3,25,000 stock options to permanent employees pursuant to ESOS 2003. Each option shall be convertible into one equity share of Re.1/- each in one or more tranches".28 Jan · Business
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding a press release dated January 28, 2008, titled "Glenmark receives US FDA approval for its state-of-the-art semi-solids manufacturing plant at Baddi". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.21 Jan · Conversion of FCCBs
Glenmark Pharmaceuticals Ltd. has informed the Exchange Vide its letter date January 21, 2008 that: "At the meeting of the Board of Directors held today, the Board has approved conversion of Zero Coupon Foreign Currency Convertible Bonds amounting to US$ 1,000,000 into 172,494 Equity shares at a price of Rs. 253.11 per share of face value Rs. 1/- each out of US $ 50,000,000 Zero Coupon Foreign Currency Convertible Bonds issued in 2005".21 Jan · Business
Glenmark Pharmaceuticals Ltd. has submitted to the exchange a copy of Management Discussion & Analysis for third quarter of the Financial Year 2007-08 ended 31st December, 2007 and Press Release dated January 21, 2008 titled "Glenmark posts a consolidated revenue growth of 53.56 per cent and consolidated revenues of Rs. 6850.77 million for Q3 FY08" A copies of the Management Discussion & Analysis and Press Release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.21 Jan · Results
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding the standalone Results for the quarter ended on 31-DEC-2007 as follows: Net Sales of Rs. 43357.92 lacs for quarter ending on 31-DEC-2007 against Rs. 20186.56 lacs for the quarter ending on 31-DEC-2006. Net Profit / (Loss) of Rs. 14642.68 lacs for the quarter ending on 31-DEC-2007 against Rs. 3017.24 lacs for the quarter ending on 31-DEC-2006.21 Jan · Results
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding the consolidated Results for the quarter ended on 31-DEC-2007 as follows: Net Sales of Rs. 67939.11 lacs for quarter ending on 31-DEC-2007 against Rs. 43802.53 lacs for the quarter ending on 31-DEC-2006. Net Profit / (Loss) of Rs. 28001.88 lacs for the quarter ending on 31-DEC-2007 against Rs. 18898.24 lacs for the quarter ending on 31-DEC-2006.14 Jan · Conversion of FCCBs
Glenmark Pharmaceuticals Ltd. has informed the Exchange Vide its letter date January 14, 2008 that: "At the meeting of Operations Committee of the Board of Directors held today, the Committee has approved conversion of Zero Coupon Foreign Currency Convertible Bonds amounting to US$ 2,000,000 into 344,988 Equity shares at a price of Rs. 253.11 per share of face value Re. 1/- each out of US $ 50,000,000 Zero Coupon Foreign currency Convertible Bonds issued in 2005".14 Jan · Business
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding a press release dated January 14, 2008, titled "Glenmark's lead molecule for Type II Diabetes GRC 8200 receives "Melogliptin" as its International Non-proprietary Name". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.2 Jan · Board meeting
Meeting on 21 Jan 2008: “Unaudited Financial Results for the qtr ended Dec 31, 2007”2 Jan · Conversion of FCCBs
Glenmark Pharmaceuticals Ltd. has informed the Exchange that: "At the meeting of Operations Committee of the Board of Directors held on December 02, 2008 the Committee has approved conversion of Zero Coupon Foreign Currency Convertible Bonds amounting to US$ 7,170,000 into 12,36,783 Equity shares at a price of Rs. 253.11 per share of face value Re. 1/- each out of US $ 50,000,000 Zero Coupon Foreign currency Convertible Bonds issued in 2005".
Dec 2007
31 Dec · Meeting
Glenmark Pharmaceuticals Ltd. has informed the Exchange that pursuant to the provisions of section 192A(2) of the Act read together with the Companies (Passing of Resolution by Postal Ballot) Rules, 2001, the consent of the shareholders to be obtained by means of Postal Ballot for the aforesaid purpose (as per attachments).The Company has appointed Mr.Surjan Singh Rauthan, Practicing Company Secretary, Mumbai, as the Scrutinizer for conducting the Postal Ballot in a Fair and transparent manner. The Postal Ballot Form duly completed and signed should reach the Scrutinizer on or before the close of working hours on January 30, 2008. The Scrutinizer shall submit his report to the Chairman of the Company after the completion of the scrutiny and the results of the Postal Ballot shall be announced on February 05, 2008. A copy of the postal ballot shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.20 Dec · Allotment of shares/ others
Glenmark Pharmaceuticals Ltd. has informed the Exchange vide its letter dated December 20, 2007 that "The Board of Directors at its meeting held today : 1) Alloted 4,05,420 Equity shares to the employees of the Company/ subsidiaries on exercise of options granted to them pursuant to ESOP'2003; 2) Approved conversion of Zero Coupon Foreign Currency Convertible Bonds amounting to US$ 29,90,000 into 5,15,757 Equity Shares at a price of Rs.253.11 per share of face value Re.1/- each out of US$ 50,000,000 Zero Coupon Foreign Currency Convertible Bonds issued in 2005; 3) Further to the communication on 07/11/2007 regarding the approval by the board for the re-organisation of the business, the board has today approved the postal Ballot notice for seeking approval of the shareholders under Section 293(1) (a) of the Companies Act, 1956".13 Dec · Business
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding a press release dated December 12, 2007, titled "Glenmark Confirms ANDA Filing with a Paragraph IV Certification for Tarka (R) Tablets". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.12 Dec · Disclosure
Glenmark Pharmaceuticals Ltd. has informed the Exchange that "The Compensation Committee of the Company, at its meeting held on 4th December, 2007 has issued 4,54,000 stock options to the employees pursuant to ESOS 2003. Each option shall be convertible into one equity share of Re.1/- each in one or more tranches. The Compensation Committee of the Company, at its meeting held on 4th December, 2007 has cancelled 34,000 stock options (adjusted after issue of bonus equity shares in the ratio of 1:1 and split of the face value from Rs.2/- to Re.1/- per share) stock options issued pursuant to ESOS 2003, owing to employees leaving the services of the Company".
Nov 2007
28 Nov · Business
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding a press release dated November 28, 2007, titled "Glenmark announces plans to expand presence in Nigeria". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.7 Nov · Business
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding a press release dated November 07, 2007, titled "Glenmark announces plan to reorganize businesses into Specialty and Generics". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.7 Nov · Miscellaneous
Glenmark Pharmaceuticals Ltd. has informed the Exchange that vide its letter dated November 7, 2007 "The Board of Directors at its meeting held today, granted its in-principle approval to re-organise the business of the Company by sale of its Generics business to its Subsidiary Company."
Oct 2007
31 Oct · Allotment of shares/ others
Glenmark Pharmaceuticals Ltd. has informed the Exchange vide its letter dated October 31, 2007 that: "The Board of Directors of the Company at its meeing held today: (1) Alloted 40,000 shares to the employees of the Company on exercise of options granted to them pursuant to ESOP 2003. (2) Approved conversion of Zero Coupon Foreign Currency Convertible Bonds amounting to US $4,500,000 into 603,728 and 202,506 Equity shares at a price of Rs. 253.11 and Rs215.5985 per share respectively of face value Re.1/- each out of US $ 70,000,000 Zero Coupon Foreign currency Convertible Bonds issued in 2005."31 Oct · Business
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding a press release dated October 31, 2007, titled "Glenmark posts a consolidated revenue growth of 50.16 per cent and consolidated revenues of Rs. 3839.47 million for Q2 FY08". A copy of the press release and Management Discussion & Analysis shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements) For more details click here.31 Oct · Dividend
Glenmark Pharmaceuticals Ltd. has informed the Exchange that the Board of Directors at their Meeting held on October 31, 2007 has declared Interim Dividend @70% on equity Share capital.31 Oct · Results
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding the consolidated Results for the half year ended on 30-SEP-2007 as follows: Net Sales of Rs. 72625.51 lacs for half year ending on 30-SEP-2007 against Rs. 42988.4 lacs for the half year ending on 30-SEP-2006. Net Profit / (Loss) of Rs. 13227.75 lacs for the half year ending on 30-SEP-2007 against Rs. 5887.49 lacs for the half year ending on 30-SEP-2006.31 Oct · Results
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding the standalone Results for the half year ended on 30-SEP-2007 as follows: Net Sales of Rs. 54221.38 lacs for half year ending on 30-SEP-2007 against Rs. 32597.93 lacs for the half year ending on 30-SEP-2006. Net Profit / (Loss) of Rs. 11245.61 lacs for the half year ending on 30-SEP-2007 against Rs. 4206.88 lacs for the half year ending on 30-SEP-2006.31 Oct · Results
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding the standalone Results for the quarter ended on 30-SEP-2007 as follows: Net Sales of Rs. 27926.68 lacs for quarter ending on 30-SEP-2007 against Rs. 19634.98 lacs for the quarter ending on 30-SEP-2006. Net Profit / (Loss) of Rs. 6386.38 lacs for the quarter ending on 30-SEP-2007 against Rs. 3205.13 lacs for the quarter ending on 30-SEP-2006.30 Oct · Business
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding a press release dated October 30, 2007, titled "Lilly and Glenmark Pharmaceuticals Announce License Agreement". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.29 Oct · Business
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding a press release dated October 29, 2007, titled "Oglemilast, Glenmark's lead molecule for Asthma / COPD receives US FDA nod to initiate further Phase II trials". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.25 Oct · Business
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding a press release dated October 25, 2007, titled "Glenmark offers the widest topical dermatology products in South Africa". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.24 Oct · Corporate action
Glenmark Pharmaceuticals Ltd. has informed the Exchange that "The Company has on Thursday 8th November, 2007 has been fixed as the record date for determining members, who would be entitled to payment of Interim Dividend on Equity Shares for the financial year 2007-2008, subject to confirmation by the Board of Directors at its meeting scheduled to be held on 31st October, 2007".23 Oct · Board meeting
To approve the Un-Audited Financial Results for the 2nd Quarter/ Half ended September 30, 2007 and inter alia may also consider payment of Interim Dividend on Equity Shares of the Company for the financial year 2007-2008.15 Oct · Conversion
Glenmark Pharmaceuticals Ltd. has informed the Exchange vide its letter dated October 15, 2007 that: "At the meeting of Operations Committee of the Board of Directors held today, the Committee has approved conversion of Zero Coupon Foreign Currency Convertible Bonds amounting to US$ 1,000,000 into 172,494 Equity shares at a price of Rs 253.11 per share of face value Rs.1/- each out of US $ 50,000,000 Zero Coupon Foreign currency Convertible Bonds issued in 2005".10 Oct · Business
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding a press release dated October 10, 2007, titled "Glenmark receives US FDA approval for the first generic version of Trileptal-Oxcarbazepine-Shared Exclusivity". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.5 Oct · Business
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding a press release dated October 05, 2007, titled "Glenmark wins Emerging Company Of The Year 2007 at The Economic Times Awards for Corporate Excellence". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Sep 2007
26 Sep · Business
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding a press release dated September 26, 2007, titled "Glenmark receives MHRA, UK approval for its state-of-the-art semi-solids manufacturing plant at Baddi". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.10 Sep · Business
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding a press release dated September 10, 2007, titled "Glenmark receives US FDA approval for the first generic version of Coreg - Carvedilol". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.6 Sep · Conversion of FCCBs
Glenmark Pharmaceuticals Ltd. has informed the Exchange vide its letter dated September 5, 2007 that : " At the meeting of Operations Committee of the Board of Directors held today, the Committee has approved conversion of Zero Coupon Foreign Currency Convertible Bonds amounting to US $ 500,000 into 43,123 Equity shares at a price of Rs. 506.22 per share of face value Rs. 2/- each out of US $ 50,000,000 Zero Coupon Foreign currency Convertible Bonds issued in 2005".
Aug 2007
30 Aug · Meeting
Glenmark Pharmaceuticals Ltd. has informed the Exchange that the Annual General Meeting of the Company will be held on September 20, 2007.30 Aug · Miscellaneous
Glenmark Pharmaceuticals Ltd. has informed the Exchange that "The Compensation Committee of the Company, at its meeting held on 22nd August, 2007 has issued 1,44,000 stock options to the employees pursuant to ESOS 2003. Each option shall be convertible into one equity share of Rs. 2/- each in one or more tranches." The Company has further informed that "the Compensation Committee of the Company, at its meeting held on August 22, 2007 has cancelled 13,100 (Adjusted after issue of bonus equity shares in the ratio 1:1) stock options issued pursuant to ESOP 2003, owing to employees leaving the services of the company".17 Aug · Corporate action
Glenmark Pharmaceuticals Ltd. has informed the Exchange that Register of Members of the Company shall remain closed from September 17, 2007 to September 20, 2007 (both days inclusive) for Annual Closure for the Annual General Meeting and for the purpose of determining the members who would be entitled to receive sub-divided shares of Re. 1 each.9 Aug · Proceedings
Glenmark Pharmaceuticals Ltd. submitted to the Exchange a copy of the proceedings of the Deemed EGM of the Company held on July 27, 2007 for declaration of results of the Postal ballot. The details shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Jul 2007
30 Jul · Miscellaneous
Glenmark Pharmaceuticals Ltd. had informed the Exchange regarding a press release dated July 30, 2007, titled "Glenmark posts for Q1 FY08, a consolidated revenue growth of 88 per cent and consolidated profits of Rs.3594.24 million". The Company has now informed the Exchange that there is a typographical mistake in the headline of the press release sent earlier. The heading to be read as "Glenmark Posts for Q1 FY08, a consolidated revenue growth of 88 per cent and consolidated revenues of Rs.3594.24 million".30 Jul · Allotment of shares
Glenmark Pharmaceuticals Ltd. has informed the Exchange that the Board of Directors of the Company, at its meeting held on July 30, 2007 allotted 28,450 shares to the employees of the Company on exercise of options granted to them pursuant to ESOS 2003.30 Jul · Business
Glenmark Pharmaceuticals Ltd. has submitted to the Exchange a copy of the presentation made at the analyst meet titled "Management Discussion and Analysis for First Quarter of the Financial Year 2007-08 ended 30th June, 2007". Further, the company has also informed the Exchange regarding a press release dated July 30, 2007, titled "Glenmark posts for Q1 FY08, a consolidated revenue growth of 88 per cent and consolidated profits of Rs.3594.24 million". The details of the both shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.30 Jul · Results
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding the consolidated Results for the quarter ended on 30-JUN-2007 as follows: Net Sales of Rs. 35135.66 lacs for quarter ending on 30-JUN-2007 against Rs. 19155.33 lacs for the quarter ending on 30-JUN-2006. Net Profit / (Loss) of Rs. 5715.13 lacs for the quarter ending on 30-JUN-2007 against Rs. 1867.37 lacs for the quarter ending on 30-JUN-2006.30 Jul · Results
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding the standalone Results for the quarter ended on 30-JUN-2007 as follows: Net Sales of Rs. 26294.7 lacs for quarter ending on 30-JUN-2007 against Rs. 13803.35 lacs for the quarter ending on 30-JUN-2006. Net Profit / (Loss) of Rs. 4859.24 lacs for the quarter ending on 30-JUN-2007 against Rs. 1001.75 lacs for the quarter ending on 30-JUN-2006.28 Jul · Results
Glenmark Pharmaceuticals Ltd. has informed the Exchange that pursuant to the notice dated June 12, 2007, the shareholders of Glenmark Pharmaceuticals Ltd have approved through postal ballot the Resolutions at the deemed Extraordinary General (EGM) held on July 27, 2007. The details of the results of the Postal Ballot shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.20 Jul · Board meeting
Meeting on 30 Jul 2007: “Unaudited financial results for quarter ended June 30, 2007”19 Jul · Conversion of FCCBs
Glenmark Pharmaceuticals Ltd. has informed the Exchange on July 19, 2007 that: "At the meeting of Operations Committee of the Board of Directors held today, the Committee has approved conversion of Zero Coupon Foreign Currency Convertible Bonds amounting to US$ 9,750,000 into 840908 Equity Shares respectively at a price of Rs. 506.22 per share of face value Rs. 2/- each out of US$ 50,000,000 Zero Coupon Foreign Currency Convertible Bonds issued in 2005".19 Jul · Business
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding a press release dated July 19, 2007, titled "Glenmark purchases rights to two therapeutic antibodies from chromos". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.